What ResMed's FY2026 10-K says: 11 signals
ResMed filed its latest 10-K with the SEC on Aug 13, 2026. It discusses acquisition completed, AI investment and compliance burden.
Public (RMD)Medical Equipment Manufacturing5,001 to 10,000 employeesresmed.comLinkedIn
- Filed
- Aug 13, 2026
- Period
- FY2026
- Fiscal year end
- 06/30
- Filings
- 1
10-K · latest 9
What ResMed's 10-K filings say
- SEC EDGAR
10-K · FY2026
Filed · Fiscal year ends 06/30 · 11 signals
ResMed divesting MatrixCare software business for $490M to focus on core growth areas
The sale is part of a portfolio optimization to sharpen focus on sleep, breathing, and connected home-based healthcare.
$490M
Sale price for MatrixCare business
software solutions
ResMed records $41.9M expense for Astral device field safety notification
A field safety notification for Astral life support devices is costing the company nearly $42 million to replace a faulty component, directly impacting gross margin.
$41.9M
Estimated costs associated with the replacement of a certain component in some Astral devices
ResMed acquired Noctrix Health in June 2026 to expand into restless legs syndrome treatment
This acquisition expands ResMed's clinical portfolio into an adjacent area of unmet need.
medical device
ResMed boosts SG&A spending by 10% on marketing and technology investments to drive growth
$126M
Year-over-year increase in SG&A expenses
10%
Constant currency increase in SG&A expenses
AIclouddigital health
SG&A spending up $126M, driven by technology investments and acquisition integration
ResMed's Selling, General & Administrative expenses rose 13% ($126M) year-over-year, explicitly due to 'technology investments' and costs to integrate the recent Noctrix and VirtuOx acquisitions.
$126M
Year-over-year increase in Selling, General and Administrative expenses
13%
Year-over-year percentage increase in Selling, General and Administrative expenses
ResMed centers its growth strategy on AI-powered digital health solutions
The company identifies itself as a global leader in AI-powered digital health and cloud-connected devices, making it a core part of its value proposition.
$47M
Year-over-year increase in Research and development expenses
14%
Year-over-year percentage increase in Research and development expenses
AIcloudsoftware
New Pillar Two global minimum tax rules have material impact on tax expense and cash flow
The implementation of new OECD tax regulations is increasing ResMed's effective tax rate from 16.5% to 20.6% and creating significant compliance complexity.
4.1%
Increase in effective income tax rate (from 16.5% to 20.6%) driven primarily by Pillar Two implementation.
ResMed increases R&D spending by 14% to $378M, signaling focus on new product innovation
The company's R&D expenses grew by $47M, driven by higher employee-related costs.
$378M
Total R&D expenses for FY2026
14%
Year-over-year increase in R&D expenses
AIcloud-connected devicesdigital health
ResMed's Rest of World revenue grows 13% to $1.7B, outpacing Americas
Revenue from outside the Americas grew to nearly $1.7B, driven by increased demand for sleep health devices and masks.
$1.7B
Rest of World net revenue for FY2026
13%
Year-over-year revenue growth in Rest of World
Showing 9 of 11 filing signals. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track ResMed with the Signal API
One POST /v1/companies/enrich call with resmed.com returns ResMed 10-K signals (sec-10k), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"resmed.com","signal_types":["sec-10k"],"limit":20}'Same industry
10-K at related companies
Questions about ResMed 10-K
When did ResMed file its latest 10-K?
What does ResMed's latest 10-K say about divestiture?
Where can I find ResMed's annual report?
Source. Annual reports (Form 10-K) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .